- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00004662
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus
OBJECTIVES:
I. Evaluate the safety and efficacy of synthetic dehydroepiandrosterone, GL701, in women with active systemic lupus erythematosus.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by participating institution.
Patients are randomly assigned to daily oral dehydroepiandrosterone or placebo for 52 weeks. Patients are evaluated every 13 weeks on study and return for a follow-up 6 weeks after completion of therapy.
Concurrent therapy with estrogen replacement and stable doses of prednisone, azathioprine, methotrexate (with folate supplementation), hydroxychloroquine, and nonsteroidal anti-inflammatory drugs is allowed. Other investigational medications and immunosuppressants are prohibited.
Studietype
Registrering
Fase
- Fase 3
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Systemic lupus erythematosus by 1982 American College of Rheumatology criteria Diagnosed for at least 6 months
Systemic Lupus Activity Measure score at least 7 Points for erythrocyte sedimentation rate excluded
SLEDAI score of greater than 2 at both screening and qualifying visits
--Prior/Concurrent Therapy--
No prior participation in any dehydroepiandrosterone (DHEA) study
No investigational agent within the longer of 30 days or 10 half-lives of the agent
Prednisone (or equivalent) dose 0 to 10 mg/day Unchanged for at least 6 weeks prior to entry
At least 3 months since immunosuppressants other than azathioprine and methotrexate, including:
- DHEA
- Adrenocorticotropin hormone
- Androgens
- Cyclophosphamide
- Cyclosporine
- Immune globulin
At least 6 weeks since change in azathioprine, methotrexate, or hydroxychloroquine
--Patient Characteristics-- Renal: No requirement for hemodialysis
Cardiovascular: No serious abnormality on electrocardiogram
Other:
- No hypersensitivity to DHEA or inactive ingredients in GL701 formulation, i.e., cornstarch, lactose, or magnesium stearate
- No history of breast cancer or reproductive tract malignancy
- Cervical carcinoma eligible if surgically cured, i.e., no evidence of disease for 5 years
- No condition that would prevent compliance or follow-up, e.g.: Alcoholism Drug addiction Acute withdrawal from chemical dependency
- Psychiatric disease
- No pregnant or nursing women
- Negative pregnancy test required of fertile women
- Reliable contraception required of fertile women
- No estrogen-containing oral contraceptives on study
- At least 3 weeks since estrogen-containing oral contraceptives
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Masking: Dobbelt
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Rosalind Ramsey-Goldman, Northwestern University
Studierekorddatoer
Studer hoveddatoer
Studiestart
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 199/11918
- NU-584
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .